RegGenome secures $6m in seed funding led by Evolution Equity Partners to advance regulatory data structures.
Evolution Equity Partners led the seed round with backing from AlbionVC, Cambridge Enterprise, and Mastercard.
≈ £4.6M at $1 = £0.7678 on 11 Apr 2022
RegGenome is a Cambridge spin-out that structures regulatory information into machine-readable data using artificial intelligence. The firm builds an open framework to help institutions manage compliance and regulatory intelligence.
RegGenome has secured $6m in seed funding to develop its regulatory data structures. Evolution Equity Partners led the round, with participation from AlbionVC, Cambridge Enterprise, and Mastercard.
The capital will support the company as it expands its AI-powered platform for converting unstructured regulatory information into machine-readable formats. Richard Seewald of Evolution Equity Partners joins the company board following the investment.
The funding follows the origins of RegGenome from the Regulatory Genome Project at the University of Cambridge. The firm aims to provide vendor-neutral data to simplify compliance and risk management across multiple jurisdictions.
From the founder
"We are thrilled to be working with a group of investors that share our view that the world is rapidly entering into a period of regulatory uncertainty, requiring interoperable content to power the next generation of regulatory applications for the digital economy,"
Robert Wardrop
Executive Chairman at RegGenome
Investor perspective
"RegGenome is a superb example of how the University of Cambridge's transformational intellectual property can be applied for global impact. RegGenome is primed to deliver a quantum leap in how regulatory content is shared and harnessed. Cambridge Enterprise has been an integral part of RegGenome from the outset, from enabling access to the required technology to investing in its funding. We are looking forward to seeing RegGenome's vision come to life,"
Marcio Siqueira
Head of Physical Sciences, Cambridge Enterprise
Use of funds
- 01Continue product development
